Table 1.

Clinical characteristics of patients.

	Sorafenib	TACE	ALL
	(n = 9)	(n = 8)	(n = 17)
Age
Median (Min,Max)	64 (53, 81)	69.5 (53, 84)	67 (53, 84)
Sex
Female	1 (11.1%)	1 (12.5%)	2 (11.8%)
Male	8 (88.9%)	7 (87.5%)	15 (88.2%)
Race
White	7 (77.8%)	7 (87.5%)	14 (82.4%)
Black	1 (11.1%)	0	1 (5.9%)
Am Indian, Aleutian, Eskimo	1 (11.1%)	0	1 (5.9%)
Asian Indian	0	1 (12.5%)	1 (5.9%)
Hepatitis B
No	9 (100%)	7 (87.5%)	16 (94.1%)
Yes	0	1 (12.5%)	1 (5.9%)
Hepatitis C
No	4 (44.4%)	4 (50%)	8 (47.1%)
Yes	5 (55.6%)	4 (50%)	9 (52.9%)
Alcohol Use
No	5 (55.6%)	6 (75%)	11 (64.7%)
Yes	4 (44.4%)	2 (25%)	6 (35.3%)
Cirrhosis
No	3 (33.3%)	4 (50%)	7 (41.2%)
Yes	6 (66.7%)	4 (50%)	10 (58.8%)
Previous Treatment
No	6 (66.7%)	6 (75%)	12 (70.6%)
Yes	3 (33.3%)	2 (25%)	5 (29.4%)
ECOG
0 = Normal, no complaints	6 (66.7%)	4 (50%)	10 (58.8%)
1 = Normal with effort	3 (33.3%)	4 (50%)	7 (41.2%)
AJCC Stage
1	2 (22.2%)	1 (12.5%)	3 (17.6%)
2	1 (11.1%)	3 (37.5%)	4 (23.5%)
3	6 (66.7%)	2 (25%)	8 (47.1%)
4A	0	2 (25%)	2 (11.8%)
BCLC Stage
B	8 (88.9%)	6 (75%)	14 (82.4%)
C	1 (11.1%)	2 (25%)	3 (17.6%)